In a momentous breakthrough within the realm of cardiovascular and pulmonary disease therapeutics, BioCardia Inc revealed today that the Food and Drug Administration (FDA) has greenlit the Phase III clinical trial of its CardiAMP autologous cell therapy, which has triggered a significant surge in the company’s stock, marking a pivotal moment for both BioCardia and the advancement of innovative treatments.
At the time of this publication, BioCardia Inc stock (BCDA) has witnessed a surge.
BioCardia Inc
Current Price: $1.31
Change : +0.91
Change (%): (228.30%)
Volume: 81.9M
Source: Tomorrow Events Market Data
This cutting-edge therapy is designed to tackle the critical challenge of ischemic heart failure, a debilitating condition that impacts a substantial number of patients. The approval signifies a significant milestone for the company, positioning them at the forefront of cutting-edge medical research and treatment.
The ongoing CardiAMP Heart Failure trial, which has already completed enrollment, is poised to provide crucial insights into the effectiveness of the CardiAMP autologous cell therapy. Final data analyses are anticipated to be reported in the fourth quarter of 2024, shedding light on the therapy’s potential impact on patients with ischemic heart failure.
An interim analysis of available data from the ongoing trial has yielded promising results. Patients with N-terminal pro B-type natriuretic peptide (NT-proBNP) levels consistent with heart failure at screening-baseline demonstrated significant clinical improvements over controls. This includes a remarkable 59% relative risk reduction in heart-related deaths and a 54% relative risk reduction in Major Adverse Cardiovascular or Cerebrovascular events (MACCE). Moreover, various clinical outcome measures favored cell therapy over guideline-directed medical therapy, including improvements in quality of life, reduced NT-proBNP levels, increased walk distance, and enhanced cardiac measures.
Notably, statistical significance (p<0.05) was observed for both the reduced heart death equivalents measure (p=0.028) and the improved quality of life measure (p=0.016). These findings underscore the potential of CardiAMP cell therapy to revolutionize the treatment landscape for ischemic heart failure. The FDA's approval of the proposed CardiAMP Heart Failure II study brings further optimism to the BioCardia team and the medical community at large. The study incorporates eligibility requirements, including a pre-specified NT-proBNP level at baseline, and modifies the primary efficacy endpoint from the ongoing trial. The CardiAMP Heart Failure II endpoint comprises a hierarchical composite assessment, including all-cause death, cardiac death equivalents, heart transplant, left ventricular assist device (LVAD) implantation, heart failure hospitalizations, worsening heart failure events treated as an outpatient, and changes in quality of life. To enhance efficiency and reduce study costs, the CardiAMP Heart Failure II study introduces modifications to simplify clinical site logistics. The interim data analyses, coupled with statistical power calculations, support the feasibility of a modestly sized clinical trial to demonstrate efficacy. "We are enthusiastic about the FDA's approval of CardiAMP Heart Failure II, which has received strong support from our clinical investigators," stated Peter Altman, PhD., BioCardia's President and Chief Executive Officer. "The positive interim trial results and the modifications made to streamline the study reflect our commitment to addressing this significant unmet clinical need efficiently." With Medicare's reimbursement support in place for both control and treatment arms, BioCardia anticipates that the financial burden of the trial will be significantly offset. The company remains optimistic about the potential of CardiAMP cell therapy to make a meaningful impact on patients suffering from ischemic heart failure. As the clinical trial progresses, the medical community eagerly awaits further insights into the transformative effects of this innovative therapeutic approach.
